Please assess the completion status of the following clinical trial:

Trial Title: Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients, 3-7 years 11 months of age.~2. Each patient's authorized legal guardian must understand the nature of the study and must provide written informed consent. Each patient must also give assent to study participation.~3. Patients must have a diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) bipolar disorder and must currently display an acute manic, hypomanic or mixed episode as determined by DSM-IV criteria. This includes the following diagnoses: 296.4x, Bipolar I Disorder, Most Recent Episode Manic; 296.6x, Bipolar I Disorder, Most recent Episode Mixed; and 296.0x, Bipolar I Disorder, Single Manic Episode, Bipolar II Disorder, Most Recent Episode Hypomanic.~4. Patients must have an initial score (at day 0) on the YMRS total score of at least 20.~5. Subjects and their caretakers should be fluent in English.~Exclusion Criteria:~1. Clinically significant or unstable hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, hematologic or other systemic medical conditions.~2. Neurologic disorders including epilepsy, stroke, or severe head trauma.~3. Clinically significant laboratory abnormalities, on any of the following tests: CBC with differential, electrolytes, BUN, creatinine, hepatic transaminases, urinalysis, thyroid indices (T3, Total T4, Free T4, TSH), and EKG.~4. Mania due to a general medical condition or substance-induced mania (DSM-IV).~5. Mental retardation (IQ \<70), evidence of Fetal Alcohol Syndrome or an Alcohol-Related Neurodevelopmental Disorder.~6. History of hypersensitivity to or intolerance of risperidone or valproate.~7. Prior history of risperidone or valproate non-response.~8. Judged clinically to be at serious suicidal risk.~9. Participation in a clinical trial of another investigational drug within 1 month (30 days) prior to study entry.~10. Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections and day 0.~    -

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Valproate (VPA) (Type: ACTIVE_COMPARATOR): VPA was administered in liquid form, matched for taste and color with the placebo. Medication was administered in a double-blinded manner on a twice-daily basis. Patients randomized to VPA were administered an initial dose of 10 mg/kg/day on a twice daily schedule beginning on day 0. VPA levels were adjusted to achieve a blood level of 80-100 lg/mL. An independent, unblinded study psychiatrist adjusted VPA doses to achieve a therapeutic level
- Risperidone (Type: ACTIVE_COMPARATOR): Risperidone was administered in liquid form matched for taste and color to the placebo. Medications were administered in a double-blinded manner on a twice-daily basis.
- Placebo (Type: PLACEBO_COMPARATOR): The placebo was administered in liquid form, matched for taste and color with the active comparator.

Based on this trial design, predict the completion outcome and termination type (if applicable).